• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, May 15, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

FEFU scientists obtained new compounds with potential antitumor effect from sea sponge

Bioengineer by Bioengineer
November 14, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: FEFU press office


Chemists from Far Eastern Federal University’s School of Natural Sciences (SNS FEFU) developed a new method to synthesize biologically active derivatives of fascaplysin — cytotoxic pigment of a sea sponge. For the first time, they got a sufficient amount of 3-bromofascaplysin and 3,10-dibromofascaplysin, which were known before but were not available for study. Basing on these compounds, scientists synthesized 14-bromoreticulatate and 14-bromoreticulatine — the derivatives of the reticulatine alkaloids. The resulting article is published in Marine Drugs.

The joint study of scientists from the Far Eastern branch of the Russian Academy of Sciences and University Medical Center Hamburg-Eppendorf has shown that 14-bromoreticulatine — obtained for the first time in FEFU — selectively affects Pseudomonas Aeruginosa bacterium, resistant to many types of antibiotics. Also, the new compound has a moderate cytotoxic activity resulting in the death of skin cancer, rectal cancer, and prostate cancer cells.

3,10-Dibromofascaplysin can suppress human prostate cancer cell’s metabolism at sevenfold lower concentrations than those that lead to their cell membranes destruction. The substance has a wide range of potential applications to selective treatment of malignant tumor, without an adverse effect on the healthy cells.

&laquoIt is important that due to the modification of the original alkaloid structure, we were able to register the variety of its mechanisms of action at greatly different concentrations. This opens up possibilities to create new antitumor drugs with selective action based on fascaplysin. Modern anti-cancer drugs have this important property implemented not sufficiently — it determines their high toxicity for the organism as a whole. Next drug generation will not affect the patients’ quality of life that bad”, said Maxim Zhidkov one of the authors of the study, associate professor of organic chemistry in SNS FEFU.

The author refined that it is too early to talk about the developing of a new drug. Scientists hope to synthesize a new series of fascaplysin derivatives based on the results of the study and to test their action in mice. The results of prospective experiments will reveal how close the researchers came to a new effective drug.

The vast part of the research related to the synthesis of target compounds was carried out by Polina Smirnova — a Ph.D. student of the Department of organic chemistry in SNS FEFU. Scientists from G.B. Elyakov Pacific Institute of Bioorganic Chemistry of the Far Eastern Branch of the Russian Academy of Sciences, Federal Scientific Center of the East Asia Terrestrial Biodiversity of the Far Eastern Branch of the Russian Academy of Sciences and University Medical Center Hamburg-Eppendorf are among other participants of the study.

Fascaplysin was first extracted from the sea sponge Fascaplysinopsis sp. in 1988 and has been intensively studied ever since. This compound has a wide range of biological activity — it strongly suppresses the growth of various types of tumor cells and has antibacterial, antifungal and even analgesic effects. However, the fascaplysin’s high toxicity to healthy cells limits its use as a drug.

Earlier, FEFU scientists have shown that fascaplysin derivatives stimulate the death of glioblastoma multiforme cells — the most aggressive type of brain cancer.

###

The study was supported by the FEFU Foundation grant No D-349-17.

Media Contact
Alexander Zverev
[email protected]

Related Journal Article

http://dx.doi.org/10.3390/md17090496

Tags: BiochemistryBiodiversityBiologyBiomedical/Environmental/Chemical EngineeringBiotechnologycancerMarine/Freshwater BiologyMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Nurse Care Reduces Hospital Use in Multimorbid Patients

May 15, 2026

Hepatitis C Elimination via Risk-Based Screening, Decentralized Care

May 15, 2026

Testing Reverse Osmosis Systems for Microbial Safety

May 15, 2026

New Study Connects Age-Related Gut Changes to Higher Disease Risk

May 15, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    843 shares
    Share 337 Tweet 211
  • New Study Reveals Plants Can Detect the Sound of Rain

    730 shares
    Share 291 Tweet 182
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    62 shares
    Share 25 Tweet 16
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nurse Care Reduces Hospital Use in Multimorbid Patients

Epinephrine vs. Saline in Neonatal Resuscitation Study

Hepatitis C Elimination via Risk-Based Screening, Decentralized Care

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.